To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
Female subjects aged 18 to 75 years (including 18 and 75 years).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histopathological diagnosed of advanced gynecological tumors.
History of another malignancy within 3 years before the first dose of study drug.
Patients with ongoing clinically significant toxicities related to prior treatment.
Presence of Grade ≥ 2 peripheral neuropathy.
Exclusion of prior diseases and prior treatments as specified in the protocol.
Single group
9MW2821+other anticancer therapy
DrugSubjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol
ORR
Objective Response Rate
DoR
Duration of Response
TTR
Time to Response
DCR
Disease Control Rate
PFS
Progression Free Survival
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
